Sequantrix

Sequantrix is a Munich-based biotech startup pioneering an AI-driven approach to treat fibrosis and chronic organ diseases. The company has built a proprietary platform combining one of the world's largest human multi-modal single-cell datasets with advanced organoid assays and animal models to discover and validate novel targets. Its initial focus is on high-mortality, high-unmet-need areas including chronic kidney disease, heart failure, and myelofibrosis, with ambitions to both develop its own pipeline and partner with pharmaceutical companies. As a young, private company, it is positioned in the pre-clinical discovery and validation stage.

Integrated 'AI-to-in vivo' platform combining a proprietary multi-modal single-cell/spatial human dataset, an AI-driven computational framework (DiseaseDecoder) for target discovery, and advanced translational models including organoids, patient-on-chip systems, and animal models.

Sequantrix competes with other AI-driven biotechs (e.g., Recursion, Exscientia, Insilico Medicine) and numerous biopharma companies focused on fibrosis and organ-specific diseases. Its differentiation lies in its specific focus on cross-organ fibrosis, its proprietary human datasets, and its integrated translational model systems for validation.